SCM
TVTX icon

Sterling Capital Management’s Travere Therapeutics TVTX Stock Holding History

Sterling Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20K Sell
674
-132
-16% -$3.95K ﹤0.01% 2027
2025
Q4 		$30.8K Buy
806
+221
+38% +$7.19K ﹤0.01% 2005
2025
Q3 		$14K Buy
585
+234
+67% +$4.4K ﹤0.01% 2319
2025
Q2 		$5.2K Sell
351
-1,100
-76% -$18.2K ﹤0.01% 2496
2025
Q1 		$26K Sell
1,451
-910
-39% -$18.5K ﹤0.01% 1583
2024
Q4 		$41.1K Buy
2,361
+2,115
+860% +$37.4K ﹤0.01% 1667
2024
Q3 		$3.44K Buy
+246
New +$2.56K ﹤0.01% 1922

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Sterling Capital Management's TVTX Position: Q1 2026 in Review

Sterling Capital Management reduced its Travere Therapeutics (TVTX) stake by 16% in Q1 2026, selling an estimated $3.95K and leaving 674 shares worth $20K. The position accounts for ﹤0.01% of the portfolio, ranked #2027.

Sterling Capital Management first reported a position in TVTX in Q3 2024 and has held it in 7 quarters since. The position peaked at $41.1K in Q4 2024. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Sterling Capital Management held 674 shares of Travere Therapeutics worth $20K as of Q1 2026.
  • Sterling Capital Management sold 132 Travere Therapeutics shares in Q1 2026, an estimated $3.95K.
  • Travere Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q1 2026, its #2027 holding.
  • Sterling Capital Management first reported a position in Travere Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Sterling Capital Management's Travere Therapeutics position peaked at $41.1K in Q4 2024.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.